H.pylori test kits (Antigen)

Name: H.pylori test kits (Antigen) - Amaris Medical Solutions
Price: 1.00 USD
Availability: InStock

$1.00

WhatsApp Order

H.pylori test kits (Antigen) are Class II medical devices (FDA-cleared/CE-marked) for rapid immunochromatographic or enzyme immunoassay detection of Helicobacter pylori antigens in stool specimens, enabling non-invasive diagnosis of active infection and post-treatment eradication confirmation. Test principles use monoclonal or polyclonal antibodies specific to H. pylori antigens, producing visible results in 10-20 minutes (rapid tests) or 1-2 hours (EIA). Sensitivity 90-98%, specificity 92-99% compared to gold standard methods. Primary clinical applications include rapid diagnosis of H. pylori infection in patients with dyspepsia, initial screening in uncomplicated dyspepsia (test-and-treat strategy), confirmation of active infection before therapy, post-treatment eradication confirmation (4-6 weeks after therapy), pediatric testing (preferred non-invasive method), screening in high-risk populations (family history of gastric cancer), and monitoring in patients with peptic ulcer disease or MALT lymphoma. Critical safety precautions include mandatory washout period (4 weeks off antibiotics, 2 weeks off PPIs) to avoid false negatives, proper specimen handling (universal precautions), refrigerated storage of kits (2-30°C), quality control verification, and disposal as biohazardous waste. Essential non-invasive tool for H. pylori management in gastroenterology and primary care.

Compare

Add to wishlist

Categories: DIAGNOSTIC EQUIPMENT, Diagnostic Kits, Lab Consumables, LABORATORY EQUIPMENT AND SUPPLIES Tags: Dyspepsia Testing, Eradication Confirmation, Gastroenteritis, Helicobacter Pylori, HpSA, HPylori Test, Stool Antigen Test

Description

H.pylori test kits (Antigen)

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Rapid Diagnosis of Helicobacter pylori Infection:

Primary Use: Provides quick detection of H. pylori antigens in stool samples, enabling diagnosis of active infection in patients presenting with dyspepsia, epigastric pain, bloating, nausea, or other symptoms suggestive of gastritis or peptic ulcer disease.
How it helps: Offers patients with chronic stomach discomfort a simple, non-invasive way to determine if H. pylori bacteria are the cause of their symptoms, guiding appropriate treatment without the need for uncomfortable procedures.

2. Initial Screening for Dyspepsia Management:

Primary Use: Used as a non-invasive first-line test in patients with uncomplicated dyspepsia, helping guide clinical management and determining need for endoscopic evaluation according to guidelines such as the Maastricht Consensus and American College of Gastroenterology recommendations.
How it helps: Helps primary care physicians make efficient decisions about patients with chronic indigestion, identifying those who need antibiotics for H. pylori and those who may need further investigation for other causes.

3. Confirmation of Active Infection:

Primary Use: Detects the presence of H. pylori antigens, which indicates active infection rather than mere serological exposure, making it valuable for confirming current infection before initiating eradication therapy.
How it helps: Ensures that patients receive antibiotics only when they have an active infection that requires treatment, avoiding unnecessary medication exposure and helping combat antibiotic resistance.

4. Post-Treatment Eradication Confirmation:

Primary Use: Performed 4-6 weeks after completion of antibiotic therapy to confirm successful eradication of H. pylori, ensuring that treatment has been effective and reducing risk of complications such as peptic ulcer recurrence or gastric cancer.
How it helps: Provides patients and their doctors with clear evidence that the course of antibiotics worked, offering peace of mind that the infection has been cleared and reducing the risk of ulcer recurrence.

5. Pediatric H. pylori Testing:

Primary Use: Non-invasive stool antigen testing is the preferred method for diagnosing H. pylori in children, avoiding the need for endoscopy and sedation, and is recommended by pediatric gastroenterology guidelines.
How it helps: Spares children from the stress and discomfort of endoscopic procedures, offering a gentle, stool-based test that is much easier for young patients and their families to accept.

6. Screening in High-Risk Populations:

Primary Use: Used to screen individuals with family history of gastric cancer, chronic atrophic gastritis, or other conditions associated with increased gastric cancer risk, enabling early detection and treatment.
How it helps: Offers a simple screening test for individuals at higher risk of stomach cancer, catching H. pylori infections early when eradication can reduce cancer risk and protect long-term health.

7. Monitoring in Patients with Peptic Ulcer Disease:

Primary Use: Serial testing may be used to confirm eradication in patients with documented peptic ulcers, ensuring healing and preventing recurrence.
How it helps: Gives patients with a history of ulcers confidence that the underlying bacterial cause has been eliminated, reducing anxiety about ulcer recurrence and the risk of complications like bleeding.

SECONDARY & SUPPORTIVE USES

1. Epidemiological Studies and Research: Used in population-based studies to determine prevalence of H. pylori infection in various geographic regions and demographic groups, contributing to public health knowledge.

2. Household Contact Screening: May be used to test family members of infected individuals in research settings or high-prevalence regions, helping understand transmission patterns.

3. Pre-Endoscopy Assessment: Results can help prioritize patients for endoscopic evaluation based on likelihood of H. pylori-related pathology, ensuring that those most likely to benefit from endoscopy are seen first.

4. Monitoring in Patients with MALT Lymphoma: Used to confirm eradication in patients with gastric MALT lymphoma, where H. pylori eradication is first-line treatment, helping guide cancer management.

5. Assessment in Unexplained Iron Deficiency Anemia: H. pylori testing is recommended in patients with unexplained iron deficiency anemia after other causes have been excluded, uncovering a treatable cause of chronic blood loss.

6. Immigrant and Refugee Health Screening: Used in some settings to screen at-risk populations from high-prevalence regions, ensuring new arrivals receive appropriate care.

7. Clinical Trials and Vaccine Studies: Utilized in research studies investigating new treatments or vaccines for H. pylori infection, contributing to the development of better therapies.

KEY PRODUCT FEATURES

1. BASIC IDENTIFICATION ATTRIBUTES

Test Type: Immunochromatographic rapid test or enzyme immunoassay (EIA) for qualitative or quantitative detection of H. pylori antigens.
Common Names: H. pylori Stool Antigen Test, HpSA Test, H. pylori Rapid Test, Stool Antigen Kit.
Sample Type: Fresh stool specimen (formed or semi-formed).
Detection Target: H. pylori antigens (typically membrane proteins or whole bacterial cells).
Methodology: Antibodies specific to H. pylori antigens immobilized on membrane capture antigens from processed stool samples, producing visible line or color change.
Kit Components:
- Test Cassettes/Devices: Individually sealed with desiccant.
- Sample Collection Tubes: With diluent buffer for stool processing.
- Droppers or Transfer Pipettes: For applying processed samples.
- Package Insert: Instructions for use and interpretation.
- Positive and Negative Controls: For quality assurance (some kits).

2. TECHNICAL & PERFORMANCE PROPERTIES

Sensitivity: 90-98% compared to gold standard (histology + culture or urea breath test).
Specificity: 92-99% with minimal cross-reactivity to other Helicobacter species or enteric pathogens.
Detection Limit: Typically detects 0.5-1.0 ng/mL of H. pylori antigens.
Time to Result:
- Rapid Tests: 10-20 minutes.
- EIA Tests: 1-2 hours (batch testing in laboratory).
Storage Temperature: 2-30°C (room temperature); do not freeze.
Shelf Life: 12-24 months depending on manufacturer.
Cross-Reactivity: Validated against common enteric pathogens (Campylobacter, Salmonella, Shigella, E. coli) to ensure specificity.

3. PHYSICAL & OPERATIONAL PROPERTIES

Test Device Format: Plastic cassette with sample well and result window (rapid tests) or microplate wells (EIA).
Sample Collection: Screw-cap tube with buffer; scoop or stick for stool collection.
Buffer Volume: Pre-measured diluent in collection tube.
Result Interpretation:
- Negative: Only control line visible.
- Positive: Both control and test lines visible.
- Invalid: No control line visible.
Packaging Sizes: Individual tests, 5-test, 10-test, 20-test, or 50-test kits.
Shelf Life Stability: Maintains performance throughout stated shelf life when stored properly.

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Status: Class II medical device requiring FDA 510(k) clearance or CE marking for IVD use.
Clinical Standards: Meets requirements of CLIA (moderate complexity) for laboratory use.
Quality Control: Built-in procedural control (control line) in each test; external controls recommended periodically.
Biohazard Precautions: All stool specimens are potentially infectious; follow standard precautions.
Chemical Safety: Buffer contains preservatives (sodium azide); avoid contact with eyes and skin.
Disposal: Used tests and contaminated materials disposed as biohazardous waste.
Storage Requirements: Must be stored at specified temperature range; do not use expired kits.

5. STORAGE & HANDLING ATTRIBUTES

Storage Temperature: 2-30°C (room temperature); protect from humidity and direct sunlight.
Sample Handling: Stool samples stable for up to 3 days at 2-8°C; longer storage requires freezing at -20°C.
Test Preparation: Bring test devices and samples to room temperature before testing.
Processing: Stool must be properly mixed with buffer per manufacturer instructions; inadequate mixing causes false negatives.
Expiration: Never use tests beyond expiration date; results invalid.
Quality Control: Test positive and negative controls with each new lot and periodically as required by laboratory protocol.
Disposal: Dispose of contaminated materials in biohazard containers.

6. LABORATORY & CLINICAL APPLICATIONS

Primary Application: Non-invasive detection of active H. pylori infection through stool antigen testing, used for initial diagnosis and post-treatment eradication confirmation.
Testing Guidelines (ACG/ESPGHAN/Maastricht):
- Test and Treat Strategy: For uncomplicated dyspepsia in young patients without alarm symptoms.
- Post-Treatment Testing: Perform 4-6 weeks after completing therapy to confirm eradication.
- Off Antibiotics: Patients must be off antibiotics for 4 weeks and off PPIs for 2 weeks before testing to avoid false negatives.
Interpretation:
- Positive: Indicates active H. pylori infection; treatment indicated.
- Negative: No evidence of active infection; consider other causes of symptoms.
- Invalid: Repeat test with new device.
Advantages: Non-invasive, avoids endoscopy, detects active infection (unlike serology), suitable for children.
Limitations: Cannot determine antibiotic susceptibility; requires off antibiotics/PPIs for accurate results.

SAFETY HANDLING PRECAUTIONS

1. SAFETY PRECAUTIONS

Biological Hazard: Stool specimens are potentially infectious for enteric pathogens (Salmonella, Shigella, Campylobacter, C. difficile, hepatitis A, norovirus). Wear gloves and appropriate PPE.
Specimen Collection: Collect in a clean, dry container; avoid contamination with urine, water, or toilet paper.
Hand Hygiene: Wash hands thoroughly after handling specimens and test devices.
Chemical Hazard: Buffer contains preservatives (sodium azide); avoid ingestion, inhalation, or contact with eyes/skin.
Quality Control: Always verify control line appears; no control line = invalid test, repeat.
PPI/Antibiotic Washout: Ensure patients have been off PPIs for 2 weeks and antibiotics for 4 weeks before testing; false negatives otherwise.
Pediatric Use: Safe for all ages; sample collection may require assistance.
Storage Compliance: Store tests at recommended temperature; heat or humidity degrades components.
Expiration: Never use expired tests; accuracy compromised.

2. FIRST AID MEASURES

Specimen Spill: Contain with absorbent material; disinfect area with 10% bleach solution; dispose as biohazard waste.
Buffer Contact (Eyes): Flush eyes with copious water for 15 minutes; seek medical attention.
Buffer Ingestion: Contact poison control center; do not induce vomiting unless instructed.
Needlestick/Sharp Injury: If injury occurs with a contaminated specimen container, wash area vigorously with soap and water; report immediately; follow institutional exposure protocol.

3. FIRE FIGHTING MEASURES

Flammability: Plastic components and packaging are combustible; buffer contains trace sodium azide.
Extinguishing Media: Use water, foam, CO₂, or dry chemical as appropriate.
Sodium Azide Hazard: Buffer contains ≤0.1% sodium azide; may react with lead/copper plumbing to form explosive azides; flush with copious water when disposing.

H.pylori test kits (Antigen)

H.pylori test kits (Antigen)

PRIMARY CLINICAL & DIAGNOSTIC USES

1. Rapid Diagnosis of Helicobacter pylori Infection:

Primary Use: Provides quick detection of H. pylori antigens in stool samples, enabling diagnosis of active infection in patients presenting with dyspepsia, epigastric pain, bloating, nausea, or other symptoms suggestive of gastritis or peptic ulcer disease.

How it helps: Offers patients with chronic stomach discomfort a simple, non-invasive way to determine if H. pylori bacteria are the cause of their symptoms, guiding appropriate treatment without the need for uncomfortable procedures.

2. Initial Screening for Dyspepsia Management:

Primary Use: Used as a non-invasive first-line test in patients with uncomplicated dyspepsia, helping guide clinical management and determining need for endoscopic evaluation according to guidelines such as the Maastricht Consensus and American College of Gastroenterology recommendations.

How it helps: Helps primary care physicians make efficient decisions about patients with chronic indigestion, identifying those who need antibiotics for H. pylori and those who may need further investigation for other causes.

3. Confirmation of Active Infection:

Primary Use: Detects the presence of H. pylori antigens, which indicates active infection rather than mere serological exposure, making it valuable for confirming current infection before initiating eradication therapy.

How it helps: Ensures that patients receive antibiotics only when they have an active infection that requires treatment, avoiding unnecessary medication exposure and helping combat antibiotic resistance.

4. Post-Treatment Eradication Confirmation:

Primary Use: Performed 4-6 weeks after completion of antibiotic therapy to confirm successful eradication of H. pylori, ensuring that treatment has been effective and reducing risk of complications such as peptic ulcer recurrence or gastric cancer.

How it helps: Provides patients and their doctors with clear evidence that the course of antibiotics worked, offering peace of mind that the infection has been cleared and reducing the risk of ulcer recurrence.

5. Pediatric H. pylori Testing:

Primary Use: Non-invasive stool antigen testing is the preferred method for diagnosing H. pylori in children, avoiding the need for endoscopy and sedation, and is recommended by pediatric gastroenterology guidelines.

How it helps: Spares children from the stress and discomfort of endoscopic procedures, offering a gentle, stool-based test that is much easier for young patients and their families to accept.

6. Screening in High-Risk Populations:

Primary Use: Used to screen individuals with family history of gastric cancer, chronic atrophic gastritis, or other conditions associated with increased gastric cancer risk, enabling early detection and treatment.

How it helps: Offers a simple screening test for individuals at higher risk of stomach cancer, catching H. pylori infections early when eradication can reduce cancer risk and protect long-term health.

7. Monitoring in Patients with Peptic Ulcer Disease:

Primary Use: Serial testing may be used to confirm eradication in patients with documented peptic ulcers, ensuring healing and preventing recurrence.

How it helps: Gives patients with a history of ulcers confidence that the underlying bacterial cause has been eliminated, reducing anxiety about ulcer recurrence and the risk of complications like bleeding.

SECONDARY & SUPPORTIVE USES

1. Epidemiological Studies and Research: Used in population-based studies to determine prevalence of H. pylori infection in various geographic regions and demographic groups, contributing to public health knowledge.

2. Household Contact Screening: May be used to test family members of infected individuals in research settings or high-prevalence regions, helping understand transmission patterns.

3. Pre-Endoscopy Assessment: Results can help prioritize patients for endoscopic evaluation based on likelihood of H. pylori-related pathology, ensuring that those most likely to benefit from endoscopy are seen first.

4. Monitoring in Patients with MALT Lymphoma: Used to confirm eradication in patients with gastric MALT lymphoma, where H. pylori eradication is first-line treatment, helping guide cancer management.

5. Assessment in Unexplained Iron Deficiency Anemia: H. pylori testing is recommended in patients with unexplained iron deficiency anemia after other causes have been excluded, uncovering a treatable cause of chronic blood loss.

6. Immigrant and Refugee Health Screening: Used in some settings to screen at-risk populations from high-prevalence regions, ensuring new arrivals receive appropriate care.

7. Clinical Trials and Vaccine Studies: Utilized in research studies investigating new treatments or vaccines for H. pylori infection, contributing to the development of better therapies.

1. BASIC IDENTIFICATION ATTRIBUTES

Test Type: Immunochromatographic rapid test or enzyme immunoassay (EIA) for qualitative or quantitative detection of H. pylori antigens.

Common Names: H. pylori Stool Antigen Test, HpSA Test, H. pylori Rapid Test, Stool Antigen Kit.

Sample Type: Fresh stool specimen (formed or semi-formed).

Detection Target: H. pylori antigens (typically membrane proteins or whole bacterial cells).

Methodology: Antibodies specific to H. pylori antigens immobilized on membrane capture antigens from processed stool samples, producing visible line or color change.

Kit Components:

Test Cassettes/Devices: Individually sealed with desiccant.

Sample Collection Tubes: With diluent buffer for stool processing.

Droppers or Transfer Pipettes: For applying processed samples.

Package Insert: Instructions for use and interpretation.

Positive and Negative Controls: For quality assurance (some kits).

2. TECHNICAL & PERFORMANCE PROPERTIES

Sensitivity: 90-98% compared to gold standard (histology + culture or urea breath test).

Specificity: 92-99% with minimal cross-reactivity to other Helicobacter species or enteric pathogens.

Detection Limit: Typically detects 0.5-1.0 ng/mL of H. pylori antigens.

Time to Result:

Rapid Tests: 10-20 minutes.

EIA Tests: 1-2 hours (batch testing in laboratory).

Storage Temperature: 2-30°C (room temperature); do not freeze.

Shelf Life: 12-24 months depending on manufacturer.

Cross-Reactivity: Validated against common enteric pathogens (Campylobacter, Salmonella, Shigella, E. coli) to ensure specificity.

3. PHYSICAL & OPERATIONAL PROPERTIES

Test Device Format: Plastic cassette with sample well and result window (rapid tests) or microplate wells (EIA).

Sample Collection: Screw-cap tube with buffer; scoop or stick for stool collection.

Buffer Volume: Pre-measured diluent in collection tube.

Result Interpretation:

Negative: Only control line visible.

Positive: Both control and test lines visible.

Invalid: No control line visible.

Packaging Sizes: Individual tests, 5-test, 10-test, 20-test, or 50-test kits.

Shelf Life Stability: Maintains performance throughout stated shelf life when stored properly.

4. SAFETY & COMPLIANCE ATTRIBUTES

Regulatory Status: Class II medical device requiring FDA 510(k) clearance or CE marking for IVD use.

Clinical Standards: Meets requirements of CLIA (moderate complexity) for laboratory use.

Quality Control: Built-in procedural control (control line) in each test; external controls recommended periodically.

Biohazard Precautions: All stool specimens are potentially infectious; follow standard precautions.

Chemical Safety: Buffer contains preservatives (sodium azide); avoid contact with eyes and skin.

Disposal: Used tests and contaminated materials disposed as biohazardous waste.

Storage Requirements: Must be stored at specified temperature range; do not use expired kits.

5. STORAGE & HANDLING ATTRIBUTES

Storage Temperature: 2-30°C (room temperature); protect from humidity and direct sunlight.

Sample Handling: Stool samples stable for up to 3 days at 2-8°C; longer storage requires freezing at -20°C.

Test Preparation: Bring test devices and samples to room temperature before testing.

Processing: Stool must be properly mixed with buffer per manufacturer instructions; inadequate mixing causes false negatives.

Expiration: Never use tests beyond expiration date; results invalid.

Quality Control: Test positive and negative controls with each new lot and periodically as required by laboratory protocol.

Disposal: Dispose of contaminated materials in biohazard containers.